Wockhardt Ltd.
Research Wockhardt Ltd. (WOCKPHARMA.NS) on Bullrun: market cap INR 317.66B, P/E 77.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerWOCKPHARMA.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 317.66B
- P/E77.6
- Financial periodQ2 2026
- RevenueINR 9.29B
- Net incomeINR 1.06B
- Gross margin65.6%
Valuation Snapshot
latest market cap is INR 317.66B; P/E is 77.6.
Peer valuation comparison
Latest P/E is 77.61x versus a Healthcare sector median of 21.74x (256.9% above).
Latest P/E is 77.61x versus a India median of 34.43x (125.4% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 317.66B | 77.6 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 INR.
About Wockhardt Ltd.
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Wockhardt Ltd.'s market cap?
Wockhardt Ltd.'s market capitalization is INR 317.66B.
What is Wockhardt Ltd.'s P/E ratio?
Wockhardt Ltd.'s price-to-earnings (P/E) ratio is 77.6.
What does Wockhardt Ltd. do?
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products.